Maze Therapeutics

Maze Therapeutics is a biopharmaceutical company that combines advanced data science methods with strong R&D capabilities to advance a series of novel precision medicines for patients with genetic diseases. Maze has developed the Maze Compass platform, a proprietary, purpose-built platform that integrates human genetic data, functional genomic tools, and data science techniques to map new connections between known genes and their impact on susceptibility, age of onset, and disease progression rates. Maze is using Compass to build a broad portfolio, including wholly-owned programs targeting Pompe disease, chronic kidney disease, and amyotrophic lateral sclerosis (ALS), as well as partnered programs in cardiovascular and ophthalmic diseases.